CDH17 and gastric adenocarcinoma: We are currently working to explore the performance of [89Zr]Zr-DFO-D2101 in murine models of stomach and gastric adenocarcinoma, to interrogate the potential of CDH17 as a target for radioimmunotherapy, to create smaller format CDH17-targeted probes that offer more rapid pharmacokinetic profiles, and to develop an improved mouse model for the study of CDH17-targeted probes.